MMD has been unsuccessful again in their infringement suit against Camco Engineering and also in their allegation that Camco contravened the Australian Consumer Law.
MMD unsuccessful again on appeal in infringement case against Camco
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Kate Legge
Kate is an experienced IP and patent lawyer, providing IP leadership for pharmaceutical product development and commercialisation in global markets – from initial scoping through to post-launch. She has developed and implemented global IP strategies over more than 15 years at multi-national pharmaceutical companies. She is an Australian qualified and registered legal practitioner, and has a Master’s degree in IP Law and a BSc in biochemistry.
See Kate's full profile
Aristocrat down to felt in the Federal Court on remitter
On 8 March 2024, Justice Burley of the Federal Court issued the latest in a series of decisions relating to the patent-eligibility of Aristocrat’s electronic gaming machine (EGM) patents. Unfortunately it does not resolve the legal uncertainty created by the High Court’s split decision on the matter in 2022. What next?
Pearce IP BioBlast w/e 26 Jan 2024
26 JAN 2024 | SG | AbbVie to Expand Biologics Manufacturing Facility in Singapore with US$223M Investment AbbVie...
Pearce IP BioBlast w/e 19 Jan 2024
19 JAN 2024 | US | Alvotech Provides Update on FDA Facility Inspection for AVT02 and AVT04 Alvotech announced that its...
Pearce IP BioBlast w/e 12 Jan 2024
12 JAN 2024 | EU | Celltrion Wins European Bids for Yuflyma® (adalimumab) and Remsima® (infliximab) Korea Biomedical...
Pearce IP BioBlast w/e 05 Jan 2024
05 JAN 2024 | AU | Celltrion’s Remsima SC®, Biobetter to Remsima®, Biosimilar to Janssen’s Remicade® (infliximab),...
If you play with fire, you might get burnt – Full Court confirms Trafalgar warning letters on invalid innovation patent breach ACL but are not unjustified threats
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Erroneous understanding of Australian law not an error qualifying for an extension of time
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 01 Dec 23
01 DEC 2023 | US | Celltrion Files BLA for Interchangeable Prolia® (Denosumab) Biosimilar with the FDA The Korea...
LAA under water – the great cost of commercialising before filing a patent application
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
“Essence or Core” of an invention – Full Court adds non-statutory element to sufficiency in first appellate decision post-RTB
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 10 Nov 23
10 NOV 2023 | EU | CHMP Positive Opinion for 8mg Eylea® (Aflibercept) Bayer announced that the EMA’s Committee for...
A hard lesson learnt: Commonwealth v Sanofi
The Australian government has made numerous claims for damages against patentees for savings forgone when an...
BioBlast w/e 15 Oct 23
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on...
Advanta succeeds again in second extension of time application opposed by Nufarm
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
When perceiving the problem is the inventive step – complacent market leader Reflex infringes disruptor Globaltech’s valid patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.